BioSpace News Archive

Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health Investors Proceeds to be used to advance lead programs in neurodegeneration and cancer Alchemab applies extremely high-throughput antibody sequencing and deep-learning to well-defined patient cohorts to identify naturally-occuring protective antibodies in people who are resilient to disease

Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET.

Canon Medical Systems USA, Inc. and RaySearch Laboratories AB are expanding their partnership to enable RaySearch’s U.S. salesforce to distribute Canon Medical’s Aquilion Large Bore CT and Celesteion PET/CT products. Together, the companies will bring their integrated radiation oncology portfolio to more U.S. customers to further enhance care for cancer patients.

Seres Therapeutics, Inc . (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.

Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that Bernat Olle, PhD, Vedanta’s Chief Executive Officer, will participate in the Executive Perspectives on Current Challenges and Opportunities for Microbiome-Based Therapeutics Panel and give a formal presentation

Series A financing co-led by Vida Ventures, T.A. Springer, and Polaris Partners with participation from EcoR1 Capital Tectonic’s proprietary technology platform based on pioneering work from the Harvard lab of co-founder, Andrew Kruse, PhD Industry veteran Alise Reicin, MD named President and Chief Executive Officer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the treatment of hospitalized patients with COVID-19.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the clinical development program for molnupiravir (MK-4482/ EIDD-2801), an investigational orally available antiviral therapeutic.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP) at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology (EADO) Congress.